Vecihi Batuman, MD, FACP, FASN
Director, Medicine Service Line, SLVHCS
Professor of Medicine
Klassen, R.B., Allen, P.L., Batuman, V., Crenshaw, K. & Hammond, T.G. Light chains are a ligand for megalin. J Appl Physiol 98, 257-63, 2005.
Arimura, A., Li, M. & Batuman, V. Potential protective action of pituitary adenylate cyclaseactivating polypeptide (PACAP38) on in vitro and in vivo models of myeloma kidney injury. Blood 107, 661-8, 2006.
Rahman, M. et al. Cardiovascular Outcomes in High-Risk Hypertensive Patients Stratified by Baseline Glomerular Filtration Rate. Ann Intern Med 144, 172-180, 2006.
Batuman, V. Fifty years of Balkan endemic nephropathy: daunting questions, elusive answers. Kidney Int 69, 644-6, 2006.
Arimura A, Li M, Batuman V. Treatment of renal failure associated with multiple myeloma and other diseases by PACAP-38. Ann N Y Acad Sci. 1070:1-4, 2006
Li M, Cortez S, Nakamachi T, Batuman V, and Arimura A. Pituitary adenylate cyclaseactivating polypeptide is a potent inhibitor of the growth of light chain-secreting human multiple myeloma cells. Cancer Res 66: 8796-8803, 2006.
Menke A, Muntner P, Batuman V, et al.: Blood Lead Below 0.48 μmol/L (10 μg/dL) and Mortality Among US Adults. Circulation, 2006
Batuman, V: Proximal tubular injury in myeloma. Contrib Nephrol, 153:87-104, 2007.
Chen, J, Gu, D, Chen, CS, Wu, X, Hamm, LL, Muntner, P, Batuman, V, Lee, CH, Whelton, PK & He, J: Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant, 22:1100-6, 2007.
Muntner, P, Menke, A, Batuman, V, Rabito, FA, He, J & Todd, AC: Association of tibia lead and blood lead with end-stage renal disease: a pilot study of African-Americans. Environ Res, 104:396-401, 2007.
Li, M, Maderdrut, JL, Lertora, JJ & Batuman, V: Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: A case study. Peptides, 2007.
1430 Tulane Ave, New Orleans, LA 70112 504-988-5187 email@example.com